COVID-19 in cancer patients: A retrospective study of 212 cases from a French SARS-CoV-2 cluster during the first wave of the COVID-19 pandemic
Ce dossier présente un ensemble d'articles concernant la prise en charge des cancers durant la crise sanitaire liée au COVID-19
We describe a large series of solid tumor patients in an early Coronavirus Disease 2019 (COVID-19) cluster of the eastern part of France. From February to May 2020, this multicenter retrospective study enrolled 212 cancer patients under treatment or on follow-up for any type of malignant solid tumor and positive for severe acute respiratory coronavirus 2. The mortality rate was 30%. Patients with gastrointestinal cancers were identified like a subset of more vulnerable cancer patients and immunotherapy or radiotherapy within 3 months from COVID-19 diagnosis were risk factors for death. The reported data support the essential need to be proactive and weigh the risks of morbidity from COVID-19 against the magnitude of benefits of intended cancer therapies during this pandemic.
The Oncologist , article en libre accès, 2020